Oxaliplatin Fresenius Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Fresenius Kabi, is a platinum‑based chemotherapy presented as a solution for intravenous use. It treats colorectal cancer and is used in adult oncology patients. GNH USA supplies Oxaliplatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

GNH USA supplies Oxaliplatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic agent that interferes with DNA replication in malignant cells.

- Colorectal cancer: used in combination regimens to shrink tumor size and improve survival rates. - Gastric cancer: employed as part of multi‑drug protocols to control disease progression. - Pancreatic cancer: incorporated in combination therapy to enhance treatment response. - Ovarian cancer: used alongside other agents to target resistant disease. - Small‑cell lung cancer: added to regimens for patients who have limited options. - Metastatic disease: applied in various solid‑tumor protocols where platinum sensitivity is demonstrated.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhea: loose stools that may require supportive care. - Fatigue: generalized tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count increasing bleed risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical attention. - Acute hemolytic anemia: rapid destruction of red blood cells. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Renal impairment: acute kidney injury, especially with dehydration. - Cardiotoxicity: arrhythmias or myocardial ischemia in susceptible patients. - Secondary malignancies: rare risk of therapy‑related cancers.

When handling Oxaliplatin, clinicians should consider several safety measures to protect patients and staff.

- Renal function monitoring: assess creatinine clearance before each cycle. - Hepatic function monitoring: check liver enzymes regularly. - Neuropathy assessment: evaluate sensory changes at each visit. - Hematologic monitoring: perform complete blood counts to detect cytopenias. - Hydration status: ensure adequate fluid intake to reduce renal toxicity. - Store at below 25°C: keep in the original packaging, protect from light and moisture.

Oxaliplatin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage. - Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may require dose adjustment for optimal control of nausea. - CYP450 inducers (e.g., rifampicin): potential reduction in drug exposure. - Radiotherapy: may amplify peripheral neuropathy. - High‑dose vitamin C: theoretical reduction in platinum‑DNA binding. - NSAIDs: possible additive effect on platelet dysfunction.